PharmiWeb.com - Global Pharma News & Resources
04-May-2021

Vividion Therapeutics Appoints Christine Siu to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.


“Christine has an impressive track record of leading both private and public biotechnology companies through critical value-creating inflection points, and we are excited to welcome her to our board of directors,” said Jeffrey Hatfield, chief executive officer of Vividion. “As Vividion continues to make progress building a company and pipeline aimed at delivering precision therapeutics for cancer and immune disorders, we look forward to leveraging her wealth of experience and unique perspectives across pipeline development, business operations, corporate strategy and growth.”

“Vividion has made tremendous advancements over the last several years, and today, the company stands in a strong position to begin realizing the value of that work,” said Ms. Siu. “I am impressed by the experienced team assembled and the science and proprietary approach aimed at addressing traditionally undruggable targets to develop therapies for patients with critical unmet needs. I look forward to partnering with the management team and board of directors to help advance the company’s deep and diversified pipeline.”

Ms. Siu brings a strong track record of creating value and integrating financing strategy with corporate development to the Vividion board of directors. Ms. Siu is the chief operating officer in-residence at BridgeBio Pharma, Inc, and former chief financial officer at Eidos Therapeutics, Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company. Prior to that, she was the chief business officer at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry. Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc. (GBT), and before that, a venture principal at Third Rock Ventures, where she was part of the GBT launch team and first employee at GBT. Previously, Ms. Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney & Partners, LLC and began her career in healthcare banking at Bear, Stearns & Co. Inc. Ms. Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.

About Vividion
Vividion Therapeutics, Inc. is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.


Contacts

Alicia Davis
THRUST Strategic Communications
alicia@thrustsc.com

Editor Details

  • Company:
    • Businesswire
Last Updated: 04-May-2021